Refine
Year of publication
Document Type
- Doctoral Thesis (70)
Language
- English (70) (remove)
Has Fulltext
- yes (70)
Is part of the Bibliography
- no (70) (remove)
Keywords
Institute
- Biochemie und Chemie (59)
- Biowissenschaften (6)
- Biochemie, Chemie und Pharmazie (3)
- Pharmazie (2)
- MPI für Biophysik (1)
The light-harvesting chlorophyll a/b protein complex (LHC-II) is the major collector of solar energy in all plants and it binds about half of the chlorophyll in green plants. LHCII is a trimer in the photosynthetic membrane; each monomer consists of 232 amino acids, binds and orients a minimum of 12 chlorophyll molecules and three caroteinoids (two luteins and one neoxanthin) for light-harvesting and energy transfer. Although, the structure of LHC-II has been determined at 3.4 Å resolution by electron microscopy of two-dimensional crystals (Kühlbrandt et al., 1994), this is not sufficient to allow a complete understanding of the mechanism of energy transfer from LHC-II to the reaction centre, since the effective resolution in the z dimension is 4.9 Å. In fact, the chemical difference between Chl a and Chl b, which has a formyl group instead of the methyl group at the 7-position in the chlorin ring, is too small to be detected at this level of resolution. In addition, the orientation of the chlorophyll tetrapyrroles have not been determined unambiguously. This information is essential for a detailed understanding of the energy transfer within the complex and to the reaction centres of photosystem II and I (PSII and PSI). X-ray crystallography of three dimensional (3D) crystals may yield a more complete structure at high resolution. 3D crystals have been grown from LHC-II isolated from pea leaves using a standard purification procedure (Burke et al., 1978). The thylakoid membranes are solubilised in Triton X-100 and further purified by sucrose gradient ultra centrifugation. The LHC-II fraction is salt precipitated and pellets resuspended at the chlorophyll a/b ratio 2.8 mg/ml in 0.9 % Nonyl-glucoside. Crystals are currently obtained by vapour diffusion in hanging drops. These crystals are thin hexagonal plates, have a fairly large unit cell and diffract quite weakly. The high level of the background is due both to the detergent, necessary for protein solubilisation, and lipids, required for the trimer and crystals formation. However, three data sets, each from one single crystal have been collected up to 3.2 Å resolution over a rotation range of 135°. The crystals were exposed to a very highly collimated and brilliant beam (ID-14 EH1 at ESRF, Grenoble, France) and were kept under a stream of cold nitrogen to prevent radiation damage. Data were successfully integrated using the program XDS by Kabsch (1993). The crystals were found to belong to the space group P6 22 3 and have unit cell dimensions of a=128.45, b=128.45, c=135.32, a= ß=90º, ?=120. The solution of the phase problem was tackled by molecular replacement using, as a search model, the LHC-II structure solved by electron cryo-microscopy studies of twodimensional crystals (Kühlbrandt et al. 1994). Three different programs were tested: the most used AMoRe (Navaza et al., 1994) and the brute force based program Brute (Fujinaga
Zwei der wichtigsten Leistungen eines sich entwickelnden Embryos sind der Aufbau des Blutkreislauf- und des Nervensystems. Beide Systeme sind hierarchisch organisierte Strukturen, deren Verzweigungen nahezu alle Teile des Körpers erreichen. Es gibt eine zunehmende Zahl von Hinweisen darauf, dass ihre Entwicklung eng miteinander verknüpft ist, nach ähnlichen Prinzipien verläuft und verwandte molekulare Mechanismen verwendet. Die Entstehung eines funktionellen vaskulären Netzwerks erfordert Signale, die Prozesse wie die Lenkung und die Verzweigung von Gefäßen in den Zielgeweben kontrollieren. Ähnliche Anforderungen werden an wachsende Axone bei der Knüpfung der Verbindungen des Nervensystems während der Embryonalentwicklung gestellt. Einige der Faktoren, die die Lenkung der Axone kontrollieren, spielen auch eine ähnliche Rolle in der vaskulären Entwicklung. Lenkungsmoleküle, die eine Richtungsinformation vermitteln, sind für die Wegfindung der Axone besonders wichtig. Die größte Familie solcher Lenkungsmoleküle wird durch die Semaphorine gebildet. Semaphorine können in acht Klassen unterteilt werden, deren gemeinsames Merkmal eine konservierte Semaphorin-Domäne ist und die unterschieden werden anhand ihrer Klassen-spezifischen carboxyterminalen Domänen. Die Semaphorin-Familie umfasst sowohl sekretierte als auch membrangebundene Proteine. Die am besten charakterisierten hiervon sind die sekretierten Klasse 3 Semaphorine. Eine Kombination von in vitro und in vivo Ansätzen zeigte, dass die Klasse 3 Semaphorine an der Steuerung der Axon- und Dendritenlenkung, der Bildung von Axonbündeln und der neuronalen Migration während der Entwicklung des Nervensystems beteiligt sind. Sie agieren hauptsächlich als repulsiv wirkende Signale, die Axone aus Regionen ausschließen, von den Geweben weg, in denen sie exprimiert sind. Diese Wirkung wird über die Semaphorin-Domäne vermittelt. Verschiedene Hinweise deuten auf eine Beteiligung von Semaphorinen an der Entwicklung des vaskulären Systems. Sowohl homozygote Sema3a- als auch Sema3c-Mausnullmutanten sterben nach der Geburt aufgrund kardiovaskulärer Defekte. Darüber hinaus binden die Rezeptoren für die Klasse 3 Semaphorine, Neuropilin-1 (Nrp-1) und –2 (Nrp-2), einige Isoformen des vaskulären endothelialen Wachstumsfaktors (Vascular Endothelial Growth Factor, VEGF). Neuropilin-1 und Neuropilin-2-defiziente Mäuse und Neuropilin-1/-2-Doppelmutanten weisen Defekte des Gefäßsystems auf, wie z.B. eine Rückbildung der neuralen Vaskularisierung und Abweichungen in der Entwicklung des Herzens und der großen Gefäße. Die membrangebundenen Semaphorine sind bisher nur wenig untersucht, da zuverlässige in vitro Assays fehlen. Somit ist ein genetischer Ansatz der beste Weg, die physiologische Funktion dieser Proteine zu untersuchen. Aus diesen Gründen war die Zielsetzung dieser Arbeit, durch homologe Rekombination in embryonalen Stammzellen eine Mauslinie herzustellen, die ein Nullallel des membrangebundenen Sema5a-Gens trägt. Für diesen Ansatz wurde ein Mitglied der Klasse 5 Semaphorine gewählt, da es nur zwei Mitglieder dieser Klasse im Mausgenom gibt, die weitgehend komplementäre Expressionsmuster aufweisen. Damit unterscheiden sie sich von den anderen Klassen der Semaphorine, deren Mitglieder stark überlappende Expressionsmuster zeigen. Dies verringert die Wahrscheinlichkeit einer gegenseitigen funktionellen Kompensation nach Mutation eines Gens. Die Klasse 5 Semaphorine sind auch deshalb besonders interessant, da sie die einzigen sind, die sowohl in Vertebraten als auch in Invertebraten vertreten sind. Sie sind gekennzeichnet durch sieben carboxyterminale Typ 1-Thrombospondinmodule (TSP) in ihrer extrazellulären Domäne. TSPs wurden ursprünglich in den Proteinen Thrombospondin 1 und 2 gefunden, in denen sie das Auswachsen von Neuriten verschiedener Nervenzelltypen fördern. Dies lässt vermuten, dass Klasse 5 Semaphorine sowohl inhibierende als auch stimulierende Effekte haben könnten, in dem sie unterschiedliche Rezeptoren mit der Semaphorin-Domäne oder der TSPs aktivieren. Das Expressionsmuster von Sema5A und die bekannte Funktion von Semaphorinen in der Ausbildung neuronaler Verbindungen lassen es sinnvoll erscheinen, bei der Untersuchung der mutanten Tiere den Schwerpunkt auf die Entwicklung des Nerven- und des Gefäßsystems zu legen. Aufgrund technischer Schwierigkeiten konnte innerhalb der Bearbeitungszeit dieser Doktorarbeit nur der Phänotyp des vaskulären Systems untersucht werden. Die Inaktivierung des Sema5a-Gens wurde durch die Verwendung eines ‚Targeting’-Vektors erreicht, welcher die Exone 4 und 5 des Sema5a-Gens durch eine Neomycin-Selektionskassette ersetzte. Aus 144 untersuchten ES-Zellklonen wurden drei ES-Zellinien mit einem rekombinierten Sema5a-Locus identifiziert. Zwei der positiven Klone wurden zur Herstellung einer chimären Maus durch die Morula-Aggregationsmethode verwendet. Mit einem der Klone konnte eine männliche Chimäre erzeugt werden, die nach Kreuzung mit NMRI-Wildtyptieren die Mutation an die Nachkommen weitergab. Der Verlust der Proteinexpression in homozygoten Sema5a-Mutanten wurde durch Westernblot-Analyse von Zellmembranpräparationen homozygoter Embryonen unter Verwendung eines Antikörpers gegen das zytoplasmatische Ende von Sema5A bestätigt. Dieses Ergebnis bestätigte, dass die Deletion des vierten und fünften Exons des Sema5a-Gens ein Nullallel hervorbringt. Nach Verpaarungen heterozygoter Mutanten konnten keine Neugeborenen identifiziert werden, die homozygot für das mutierte Allel waren. Homozygte Mutanten starben zwischen E11,5 und E12,5 der Embryonalentwicklung, der Verlust von Sema5A ist also embryonal letal. Die Morphologie der homozygoten Tiere zeigte keinen offensichtlichen Unterschied zu den heterozygoten Embryonen oder zu Wildtyp-Geschwistern auf. Frühe embryonale Musterbildungsprozesse in Sema5a-Nullmutanten sind also nicht gestört. Ein Tod bei dieser Entwicklungsstufe deutet auf einen Defekt in der Entwicklung des Blutgefäßsystems hin, da die Embryonalstadien zwischen E9 und E13 besonders wichtig für die Ausbildung dieser Gefäße sind und viele Mutationen, die Herz und Blutgefäßen beeinträchtigen, den Tod der Embryonen in diesem Stadium bewirken. Das embryonale Blutgefäßsystem in E10,5 und E11,5 Embryonen wurde durch immunhistochemische Färbungen ganzer Embryonen unter Verwendung eines spezifischen gegen das Platelet Endothelial Cell Adhesion Molecule (PECAM) gerichteten Antikörpers dargestellt, welches in vaskulären Endothelzellen exprimiert ist. Die allgemeine Architektur des Gefäßsystems war in homo- und heterozygoten Mutanten ähnlich und wies weder an E10,5 noch an E11,5 besondere Abweichungen auf. Es wurden bei der Lage und der Anzahl intersomitischer Gefäße, der Entwicklung der dorsalen Aorta oder der Vaskularisierung der Extremitätenanlagen keine Abweichungen festgestellt. Morphologische Defekte konnten jedoch bei E10,5 in den Verästelungen der Blutgefäße detektiert werden, die von den Hauptvenen der Cranialregion abzweigen. Die Verzweigungen waren geringer ausgeprägt als in heterozygoten oder Wildtyp-Vergleichstieren. Insbesondere zeigte sich eine Verringerung der Anzahl sekundärer und tertiärer Verzweigungen. In dem sich entwickelnden Embryo führt die wiederholte Verzweigung von Ästen der Hauptvenen zu einem hierarchisch gegliederten Netzwerk großer Gefäße in der Region des medialen Kopfes. Während die Ausbildung dieses Netzwerkes in den Sema5a-/--Tieren beeinträchtigt ist, erscheint die Organisation der kleinen Gefäße in den mehr dorsal und peripher gelegenen Regionen des Kopfes normal. In heterozygoten und homozygoten Mutanten bilden die kleineren Gefäße ein dicht verzweigtes Netzwerk. Die Verminderung der Komplexität der größeren Gefäße konnte in allen untersuchten Nullmutanten beobachtet werden. Es variierte jedoch die Penetranz des Phänotyps. In allen Fällen war die Anzahl primärer Verzweigungen unverändert, während die Anzahl der sekundären und der tertiären Verzweigungen zu unterschiedlichen Graden reduziert war. Im Gegensatz dazu zeigte sich im Verzweigungsmuster von heterozygoten Mutanten und beim Wildtyp nur eine geringe Variabilität zwischen individuellen Embryonen. Dies belegt, dass die Verminderung des Verzweigungsgrades größerer Gefäße nicht innerhalb der normalen Variabilität liegt, sondern durch die Inaktivierung des Sema5a-Gens verursacht wird. Dieser Phänotyp ist in späteren Stadien sogar deutlicher ausgeprägt. In E11,5 Embryonen waren die Stämme der großen Blutgefäße in den Nullmutanten weniger komplex und in einigen Fällen trat sogar eine Reduzierung der Anzahl primärer Verzweigungen auf. Diese spätere Verminderung der Anzahl bereits ausgebildeter primärer Verzweigungen legt nahe, dass der Phänotyp durch eine Rückbildung von Verzweigungen aufgrund möglicher Defizite in deren Reifung und/oder Stabilisierung erfolgt. Die interessanteste Besonderheit der vaskulären Defekte in den Nullmutanten liegt in ihrer regionalen Spezifität. Bis hier ist das Netzwerk großer Gefäße, welches der anterioren Hauptvene entspringt, das einzige Gefäßsystem, in dem Abweichungen entdeckt wurden. Dieses Netzwerk wird durch die strukturelle Umbildung des primären kapillaren Plexuses gebildet. Zwischen E9,5 und E12 sprießen Zweige rostral aus der Hauptvene, um ein hierarchisch organisiertes Netzwerk von Gefäßen zu bilden. Die Umbildung des primären kapillaren Plexus in den mehr rostral und ventral gelegenen Kopfregionen führt zu der Bildung eines hochverzweigten vaskulären Netzwerkes, welches jedoch bei E10,5 noch nicht hierarchisch organisiert erscheint. Die Signale, die für diesen unterschiedlichen Ablauf der Musterbildung während der Entwicklung des Gefäßsystems des Kopfes verantwortlich sind, sind noch unbekannt. Die besonderen Defekte in der stereotypischen Organisation der cranialen Gefäße in Sema5a-Mutanten legt nahe, dass Sema5A eines dieser Signale sein könnte. Es könnte Teil eines Rezeptor/Ligandenkomplexes sein, welcher positionelle Signale für das Verzweigen und das Wachstum großer Gefäße in rostraler Richtung liefert. Sema5A könnte die Bildung von Verzweigungen durch die Regulierung der Wanderung endothelialer Zellen, ihrer Proliferation oder ihrer Interaktion mit unterstützenden Zellen oder der extrazellulären Matrix kontrollieren. Sema5A könnte Teil eines neuen Signalweges sein oder als Teil eines der bekannten Signalwegs wirken, welcher die Entwicklung des Gefäßsystems reguliert. Einer der Signalwege, die essentiell für die Gefäßbildung sind, wird durch VEGF und Angiopoietin (Ang-1) reguliert. Sowohl in VEGF-, als auch in Ang-1-Mutanten ist die Gefäßumbildung im Kopf beeinträchtigt. Insbesondere erscheint das Netzwerk kleiner Gefäße in den Ang-1 Nullmutanten als nur nur teilweise restrukturiert und die großen Gefäße als weniger komplex. Das Verzweigungsmuster der großen Gefäße in den Ang-1- Nullmutanten ähnelt auffallend dem der Sema5a-Nullmutanten. Eine zweite Ähnlichkeit in den Phänotypen von Ang-1- und Sema5a-Mutanten zeigt sich in der Reduzierung der primären Verzweigungen, welche in den Sema5a-Nullmutanten bei E11,5 beobachtet wird. Hier könnte die Verminderung aus einer Rückbildung von Gefäßen resultieren, wie sie auch typischerweise in Mutanten für Ang-1 oder dessen Rezeptor auftritt. Diese Beobachtung legt nahe, dass Sema5A ein neuer Teilnehmer innerhalb des Ang-1-Signalweges ist, welcher die Auswirkung von Ang-1 auf die endothelialen Zellen der großen Gefäße entweder vermittelt oder moduliert und dadurch das spezifische Muster der Blutgefäße des Kopfes beeinflußt. Mit dieser Doktorarbeit wird zum ersten Mal eine funktionelle Untersuchung des Klasse 5 Semaphorins Sema5A vorgestellt. Die phänotypische Untersuchung von Mäusen, die Nullallele für Sema5a-Gens tragen ergab, dass dieses membrangebundene Protein essentiell für die embryonale Entwicklung ist. Es ist an der Musterbildung des Gefäßsystems beteiligt. Seine Aufgabe besteht möglicherweise darin, die Bereitstellung positioneller Signale für die Ausbildung von Gefäßverzweigungen zu gewährleisten. Einige grundlegende Fragen werden durch diesen Phänotyp aufgeworfen. Sowohl die Ursache für die embryonale Sterblichkeit als auch die zellulären Prozesse, welche in den Sema5a-Nullmutanten beeinträchtigt sind, müssen noch beschrieben werden. Unbekannt ist ebenfalls, ob zusätzlich zu der hier beschriebenen Rolle von Sema5A in der Gefäßbildung dieses an der Entwicklung des Nervensystems beteiligt ist. Die ersten Daten über die physiologische Rolle von Sema5A, welche mit dieser Arbeit vorgelegt werden, öffnen den Weg für weitergehende Untersuchungen über die Funktion des Proteins während der Embrionalentwicklung. Das hier erstmals vorgestellte Modellsystem ermöglicht es, Sema5A regulierte zelluläre Mechanismen zu untersuchen. Zusätzlich stellt es ein Werkzeug zur Verfügung, um die funktionelle Beziehung zwischen der Entwicklung des kardiovaskulären Systems und des Nervensystems zu untersuchen. Damit können die Aufgaben der Semaphorin-Proteinfamilie, die an diesen beiden wichtigen Prozessen beteiligt sind, näher charakterisiert werden.
The endothelin B receptor belongs to the rhodopsin-like G-protein coupled receptors family. It plays an important role in vasodilatation and is found in the membranes of the endothelial cells enveloping blood vessels. During the course of this work, the production of recombinant human ETB receptor in yeast, insect and mammalian cells was evaluated. A number of different receptor constructs for production in the yeast P. pastoris was prepared. Various affinity tags were appended to the receptor N-and C-termini to enable receptor detection and purification. The clone pPIC9KFlagHisETBBio, with an expression level of 60 pmol/mg, yielded the highest amount of active receptor (1.2 mg of receptor per liter of shaking culture). The expression level of the same clone in fermentor culture was 17 pmol/mg, and from a 10L fermentor it was possible to obtain 3 kg of cells that contained 20-39 mg of the receptor. For receptor production in insect cells, Sf9 (S. frugiperda) suspension cells were infected with the recombinant baculovirus pVlMelFlagHisETBBio. The peak of receptor production was reached at 66 h post infection, and radioligand binding assays on insect cell membranes showed 30 pmoL of active receptor /mg of membrane protein. Subsequently, the efficiency of different detergents in solubilizing the active receptor was evaluated. N-dodecyl-beta-D-maltoside (LM), lauryl-sucrose and digitonine/cholate performed best, and LM was chosen for further work. The ETB receptor was produced in mammalian cells using the Semliki Forest Virus expression system. Radioligand binding assays on membranes from CHO cells infected with the recombinant virus pSFV3CAPETBHis showed 7 pmol of active receptor /mg of membrane protein. Since the receptor yield from mammalian cells was much lower than in yeast and insect cells, this system was not used for further large-scale receptor production. After production in yeast and insect cells, the ETB receptor was saturated with its ligand, endothelin-1, in order to stabilize its native form. The receptor was subsequently solubilized with n-dodecyl-beta-D-maltoside and subjected to purification on various affinity matrices. Two-step affinity purification via Ni2+-NTA and monomeric avidin proved the most efficient way to purify milligram amounts of the receptor. The purity of the receptor preparation after this procedure was over 95%, as judged from silver stained gels. However, the tendency of the ETB receptor produced in yeast to form aggregates was a constant problem. Attempts were made to stabilize the active, monomeric form of the receptor by testing a variety of different buffer conditions, but further efforts in this direction will be necessary in order to solve the aggregation problem. In contrast to preparations from yeast, the purification of the ETB receptor produced in insect cells yielded homogeneous receptor preparations, as shown by gel filtration analysis. This work has demonstrated that the amounts of receptor expressed in yeast and insect cells and the final yield of receptor, isolated by purification, represent a good basis for beginning 3D and continuing 2D crystallization trials.
In this study we investigated the regulation of IL-18BPa by IFN-y in the context of colon cancer and human autoimmune diseases. IL-18BPa is a naturally occuring inhibitor that counteracts IL-18 bioactivity. By enhancing IFN-y production IL-18 has been introduced as pivotal mediator of TH1 immune responses. Indeed, many IL-18 effects are mediated by IFN-y. IL-18 bioactivity is connected with the pathogenesis of different inflammatory diseases, for instance, septic shock, colitis, Crohn's disease, myasthenia gravis, multiple sclerosis, rheumatoid arthritis, atherosclerosis, and organ transplant rejection. In addition, IL-18 has tumor-suppressive properties. IFN-y induced IL-18BPa expression was shown on protein and mRNA level in different colon carcinoma cell lines, organ cultures of colonic intestinal biopsy specimens, HaCaT keratinocytes as well as rheumatoid arthritis fibroblastlike synoviocytes (RA-FLS). The IFN-y-mediated induction of IL-18BPa appears to be a more general phenomenom. The capability of IFN-y to induce IL-18BPa also has been confirmed on the promoter level by performing luciferase reporter gene studies with two IL- 18BP promoter fragments. A GAS-site proximal to the transcription start site has been identified to be relevant for IFN-y-mediated induction of these two IL18BP promoter fragments. The induction of IL-18BPa is most likely mediated by STAT-1 in DLD-1 colon carcinoma cells. Sodium butyrate inhibited IFN-y-induced IL-18BPa expression in these cells. On the basis of our observations, we postulate a negative feedback mechanism, by which IFN-y-dependent and -independent IL-18 action might be counterregulated. In this model sodium butyrate is an additional player, that may interrupt the postulated negative feedback loop. A coculture system was performed to simulate an inflammatory TH1 response. This model which is more close to the in vivo situation, confirmed upregulation of IL-18BPa by endogenously produced IFN-y. The role of IL-18BPa is manifold and depends on IL-18 function in each particular case. In autoimmune diseases, for instance, which are often characterized by a TH1 polarized immune response, IL-18BPa might counterregulate IL-18 and/or IL-18-induced IFN-y bioactivity. Important examples are Crohn's disease and rheumatoid arthritis. In CD therapeutic use of IL-18BPa may therefore restore a hypothetically disturbed IL-18/IL-18BP balance. Concerning RA, IL-18BPa expression might contribute to protective functions of IFN-y, observed in different murine models for arthritis and in rheumatoid arthritis patients. Moreover, IL-18BPa might inhibit IL-18-mediated induction of subsequent cardinal inflammatory cytokines responsible for the pathogenesis of these diseases. Indeed, the pharmaceutical industry successfully used IL-18BP as therapeutic agent in a murine model of RA and in phase I clinical trials. On the contrary, in the context of carcinogenesis IFN-y- mediated IL-18BPa expression might be disadvantageous. By counterregulating the IL-18 arm of immune defenses against tumors, IL-18BP may have the potential to promote carcinogenesis. Our hypothesis is underlined by the observation that sodium butyrate, known to be protective in colon cancer, inhibited IFN-y-induced IL-18BPa expression. In parallel, IL-18-induced IFN-y is also responsible for iNOS induction. iNOS-derived NO provides a second possible way for inhibition of IFN-y-dependent and -independent tumor suppressive effects of IL-18. Finally, IFN-y-induced IL-18BPa expression was confirmed on the promoter level. This induction on the promoter level was associated with STAT-1 binding to the GAS element proximal to the start of transcription. It is tempting to speculate that blockage of the cytokine cascade upstream of IL-1 and TNF- a on the level of IL-18 may be of therapeutic benefit. Our data reflect the relationship between inflammation and cancer, in that inflammatory cells and cytokines found in tumors are likely to contribute to tumor growth, progression, and immunosuppression than they are to mount an effective host antitumour response.
Ligands of Iron-Sulphur Cluster N2: In this work the ubiquinone reducing catalytic core of NADH:ubiquinone oxidoreductase (complex I) from Y. lipolytica was studied by a series of point mutations replacing conserved histidines or arginines in the 49-kDa subunit. Although the missing 4th ligand of cluster N2 could not be found in the 49-kDa subunit of complex I, it was clearly demonstrated that iron-sulphur cluster N2 resides directly on the interface between the PSST and 49-kDa subunits. The results presented in this work show that residues in the 49-kDa subunit have strong influence on this redox centre and also on catalytic activity. The strong influence of Arg-141 and His-226 residues in 49-kDa subunit on this cluster can be deducted from complete loss of N2 signals in EPR spectra such as in case of mutants H226A and R141A. In the case of mutant H226M the EPR signal from cluster N2 was shifted and cluster N2 even lost the pH dependence of its redox midpoint potential and became more similar to the other so called 'isopotential' clusters. Specifically in the case of mutants R141M and R141K the characteristic signature of cluster N2 became undetectable in EPR spectra. However, specific dNADH:DBQ oxidoreductase activity that could be inhibited with the specific complex I inhibitors DQA and rotenone was not absolutely abolished but rather reduced. These reductions in complex I activity did not correspond to similar reductions in the specific EPR signal of cluster N2 as it was observed in the His-226 mutant series. No indications could be found that these mutations had modified the magnetic properties of cluster N2, resulting in different EPR spectra. From these observations it could be concluded that both mutants R141K and R141M virtually or entirely lack iron-sulphur cluster N2. The rates in complex I activity could be reconciled with electron transfer theory: After removal of a single redox centre in a chain, electron transfer rates are predicted to be still much faster than steady-state turnover of complex I. These results from mutants R141K, R141M and also the result from mutant H226M that protons are being pumped even if the redox midpoint potential of cluster N2 is not pH dependent questions the prominent role in the catalytic mechanism of complex I that has been ascribed to cluster N2. Histidine 91 and 95 were found to be absolutely essential for activity of complex I since in both mutants complex I was fully assembled and artificial NADH:HAR activity was parental whereas complex I specific dNADH:DBQ activity was abolished. The signal from cluster N2 in EPR spectra was parental for all His-91 and -95 mutants. Mutations at the C-terminal arginine 466 affected ubiquinone affinity and inhibitor sensitivity but also destabilised complex I. All these results provide further support for a high degree of structural conservation between the 49-kDa subunit of complex I and the large subunit of water soluble [NiFe] hydrogenases. Remodelling of Human Pathogenic 49-kDa Mutations in Y. lipolytica: Y. lipolytica has been proven a good system for studying complex I properties and thus also for studying defects that occur in humans. In this work pathogenic mutations in the 49-kDa subunit of complex I were recreated and studied. The P232Q mutant showed non-assembly of complex I and this is probably the cause why this mutation was lethal in patients. The mutants R231Q and S416P were parental for the content, artificial and also specific complex I activity, Km for DBQ and IC50 for DQA. From these results we can conclude that these two residues Arg-228 and Ser-413 in mammalian cells have specific structural importance for the 49-kDa subunit even if they are not directly involved in catalytic process.
Proton-translocating NADH:ubiquinone oxidoreductase (complex I) transports two electrons from NADH to membranal ubiquinone: in this process protons are translocated across the membrane, producing 40% of the total proton gradient between matrix side and intermembrane space. Mitochondrial complex I contains at least 46 subunits in mammals, and has a molecular weight of around 1000 kDa. Electronic microscopy analysis showed that complex I has an L-form, which consists of two domains: a peripheral “arm” (hydrophilic domain) and a membrane “arm” (hydrophobic domain). The peripheral domain, which protrudes into the matrix, contains one non-covalently bound flavin mononucleotide (FMN) and the iron-sulfur clusters N1a, N1b, N2, N3, N4 and N5 as redox active groups. They transport electrons from NADH to ubiquinone. Cluster N2 is supposed to be the immediate electron donor to ubiquinone by virtue of its highest and pH dependent redox midpoint potential (Em,7 –150 mV). The exact location of the tetra-nuclear cluster N2 is still object of discussion. The TYKY and the PSST subunits contain three binding motifs for tetranuclear clusters which are formed by twelve cysteins. In an effort to investigate the “ubiquinone reduction module” of complex I, in the first part of this work site directed mutagenesis of the TYKY and PSST subunits has been carried out. Mutant strains were characterised in terms of complex I content, catalytic activity and EPR signature of cluster N2. The second part of this work was aimed at developing a substrate inducible version of the internal alternative NADH:ubiquinone oxidoreductase (NDH2i). A substrate inducible NDH2i is expected to offer a “switch” between complex I activity dependent (no NDH2i activity) and independent (NDH2i activity) cell growth, by changing between activating and non-activating substrates. This strategy would allow the screening for two types of complex I mutants, which is a prerequisite for realising a random PCR mutagenesis of single subunits of complex I, that allows the production of a high number of point mutations in relatively short time. Y. lipolytica complex I deficiency mutant strains could be easily identified, by virtue of their inability to survive under complex I dependent growth conditions (no NDH2i activity). By this way, amino acids that have an important role for complex I structure or function could be identified by subsequent sequence analysis. Each of the twelve cysteines that form the above mentioned three binding motifs for iron-sulfur cluster have been mutagenised. In mutant mitochondrial membranes, no assembled complex I could be detected. From these data one may conclude that the mutagenised 6 SUMMARY 92 cysteines play an important role for complex I stability, or that are a prerequisite for complex I assembly in Y. lipolytica, but there is not direct evidence indicating that any of the four mutagenised residues acts as a ligand. Two aspartates in the PSST subunit, Asp-99 and Asp-115, were found to be essential for complex I catalytic activity. EPR spectroscopic analysis indicated that the electron transfer to N2 cluster was not blocked and implied that this was not the reason for the loss of catalytic activity. From these data it can be concluded that D99 and D115 play a vital role for complex I NADH:ubiquinone reductase activity, but are not ligands for cluster N2 and that their position is not close enough to the cluster to influence directly its electromagnetic environment. Three mutations, identified in the PSST and TYKY homologous subunits of patients affected with Leigh syndrome (V119M in PSST, P78L and R101H in TYKY) were reconstructed in the obligate aerobic yeast Y. lipolytica. This approach may help to understand the aetiology of the Leigh syndrome, in terms of the ability of complex I to oxidize NADH and to transport electrons. In fact, all three mutations showed effects on electron transport, reducing the VMax by about 50%. Mutant V119M in the PSST subunit, which had a lethal effect in two patients that were homozygous for this mutation, affects a fully conserved residue. Overall, the results from site directed mutagenesis carried out so far support the theory that the “catalytic core ” (N2 cluster and quinone binding site) of complex I has been evolved from the electron transfer module of the [Ni-Fe] hydrogenases. In fact, mutagenesis of residues that are fully conserved between complex I and [Ni-Fe] hydrogenases, showed dramatic effects on complex I in terms of assembly (cysteine mutants) or catalytic activity (D99-D115). Differently, changing aspartate 174 and glutamic acid 185 (not fully conserved, Fig 4.1A) had little or no effect on the Michaelis-Menten parameters and N2 EPR signal. In recent years Y. lipolytica has been developed as a yeast genetic system to study mitochondrial complex I. The present work introduced the promoter for the isocitrate lyase (pICL1) as a useful tool for the substrate selective expression of the internal version of the alternative NADH:ubiquinone oxidoreductase (pICL1-NDH2i). This allows to rescue complex I deficiencies “in vivo” selectively by growth on acetate (or ethanol) medium. The integration of the pICL1-NDH2i construct into the genome of Y. lipolytica and subsequent deletion of nuclear-coded subunits like PSST, TYKY and 49 kDa, would contribute to further develop this organism as a useful genetic model for studying subunits of mitochondrial complex I by site directed mutagenesis.
Nitric oxide (NO) represents a short-lived mediator that pivotally drives keratinocyte movements during cutaneous wound healing. In this study, we have identified p68 DEAD box RNA helicase (p68) from a NO-induced differential keratinocyte cDNA library. Subsequently, we have analyzed regulation of p68 by wound-associated mediators in the human keratinocyte cell line HaCaT. NO, serum, growth factors and pro-inflammatory cytokines were potent inducers of p68 expression in the cells. p68 was constitutively expressed in murine skin, but rapidly down-regulated upon injury. The down-regulation appeared to be transient, as p68 protein expression increased again after the inflammatory phase of repair. However, p68 protein expression did not completely disappear during wound inflammation, as immunohistochemistry and cell fractiona tion analysis revealed a restricted localization of p68 in keratinocyte nuclei of the developing epithelium. In line, cultured human (HaCaT) and murine (PAM 212) keratinocyte cell lines showed a nuclear localization of the helicase. Moreover, confocal microscopy revealed a strong localization of p68 protein within the nucleoli of the keratinocytes. Functional analyses demonstrated that p68 strongly participates in keratinocyte proliferation and gene expression. Keratinocytes that constitutively overexpressed p68 protein were characterized by a marked increase in serum-induced proliferation and vascular endothelial growth factor (VEGF) expression, whereas down-regulation of endogenous p68 using small interfering RNA (siRNA) markedly attenuated serum-induced proliferation and VEGF expression. Altogether, our results suggest a tightly controlled expression and nucleolar localization of p68 in keratinocytes in vitro and during skin repair in vivo that functionally contributes to keratinocyte proliferation and gene expression.
The cytochrome bc1 complex or ubiquinol:cytochrome c oxidoreductase (QCR) catalyses electron transfer from ubiquinol to cytochrome c in respiration and photosynthesis coupled to a vectorial proton transport across the membrane, in which the enzyme resides. In both bacteria and eukaryotic organisms, QCR participates in supramolecular assembly of membrane proteins that comprise the respiratory or photosynthetic chain. In the present work, proton transfer pathways, substrate binding and the supramolecular assembly of the respiratory chain in yeast were probed by structure-based site-directed mutagenesis and characterization of the variants. Both active sites centre P, the place of quinol oxidation, and centre N, where quinone reduction takes place, lack direct access to the bulk solvent necessary for proton release and uptake. Based on the X-ray structure, proton transfer pathways were postulated. Analysis at centre P showed, that E272 and Y132 of cytochrome b are important for QCR catalysis as indicated by increased superoxide production and lowered Cyc1p reductase activity in these variants. Pre-steady state heme reduction kinetics in combination with stigmatellin resistance indicated that charge and length of the side chain at position 272 are crucial for efficient docking of the ISP to form the enzyme substrate complex and for electron bifurcation at centre P. Variants of Y312 and F129, both residues of cytochrome b, showed an increased Km indicating participation of these residues in coordination of ubiquinol or the possible intermediate semiquinone anion radical. F129 proved to be crucial for a functional Q-cycle as indicated by respiratory negative growth phenotype and a lowered H+/e- stoichiometry of F129 variants. At centre N, the postulated CL/K and E/R proton transfer pathways are located at opposite sites of the bound ubiquinone. Variants in the surface residues R218 (cytochrome b) and E52 (Qcr7) of the E/R pathway and E82 (Qcr7) of the CL/K pathway showed instability upon purification indicating an important role of these residues for QCR integrity. The slowed down centre N reduction kinetics in H85 (CL/K), R218 and N208 (both E/R) variant was attributed to a destabilised semiquinone anion consistent with the observed decreased sensitivity towards the site-specific inhibitor antimycin and an increased Km. Variants of residues of both pathway, E82Q and R218M, exhibited a decreased H+/e- stoichiometry indicating a crucial role of both residue for maintaining a working Q-cycle and supporting the proposed protonation of the substrate via the Cl/K and the E/R pathway. Long-range interaction between centre N and centre P were observed by altered reduction kinetics of the high potential chain and increased superoxide production in the centre N variants. The role of the cation-pi-interaction between F230 of Cyt1p and R19 of cytochrome c in binding of the redox carrier to QCR was analysed. In F230L hydrophobic interaction were partially lost as was deduced from the ionic strength dependence of Cyc1p reductase activity and Cycp1 binding, as detected by ionic strength sensitive Kd and Km for Cyc1p. The decreased enzymatic rate of F230W could be explained by a disturbed binding of Cyc1p to the variant enzyme. F230 may influence the heme mid point potential and thereby the electron transfer rate to Cyc1p. Reduction of Cobp via both centre P and centre N was disturbed suggesting an interaction between high and low potential chain. Supramolecular association between QCR and cytochrome c oxidase (COX) in yeast mitochondria was probed by affinity chromatography of a his-tagged QCR in the presence of the mild detergent digitonin. In comparison to purification with laurylmaltoside, the presence of both QCR and COX subunits was detected in the elution fractions by SDS-PAGE, Cyc1p reductase and TMPD oxidase activity assays and immunoblot analysis. The CL-dependent formation of the supercomplex between QCR and COX was analysed by replacement variants in the CL-binding site of QCR in CL containing and CL free environment. With an increasing number of replacements of the three lysines the CL-binding pocket supercomplex formation was not abolished, when CL is present as shown by BN-PAGE analysis. This was supported by the synergetic decrease in enzyme activity for both enzymes upon increased number of replacements. In the CL-free environment, no supracomplex formation was observed for a wildtype CL binding site. By replacements of two lysines in the CL-binding pocket, supercomplex formation could be recovered as revealed by BN-PAGE. This indicates, that CL may serve as a charge neutralizer for the lysines near the presumed interaction domain between complex III and complex IV. The obtained results for centre P provide new information of residues critical for stabilisation of ubiquinol and controlling electron short circuit reactions. The observations for centre N variants clearly support the proposed two proton transfer pathways and the role of the bound phospholipids in centre N kinetics. Variants in the Cyc1p binding site suggest a role for F230 both in Cyc1p binding and electron transfer. Clear interaction between the high and low potential chain in both Cyt1p and centre N variants strongly support long-range interactions in the complex. Studies on the supramolecular association of complex III and complex IV indicate a new role of Cl in stabilising a supracomplex.
The cytochrome bc1 complex is a cornerstone in bioenergetic electron transfer chains, where it carries out tasks as diverse as respiration, photosynthesis, and nitrogen fixation. This homodimeric multisubunit membrane protein has been studied extensively for several decades and the enzyme mechanism is described with the modified protonmotive Q cycle. Still, the molecular and kinetic description of the catalytic cycle is not complete and questions remain regarding the bifurcation of electron transfer at the quinol oxidation (Qo) site, substrate occupancy, pathways of proton conduction, and the nature of the Rieske protein domain movement. We used competitive inhibitors to study the molecular architecture at the Qo site with X-ray crystallography. The structure of the enzyme with the substrate analog 5-n-heptyl-6-hydroxy-4,7-dioxobenzothiazole (HHDBT) bound at the Qo site was determined at 2.5 Å resolution. Spectroscopic studies showed that HHDBT is negatively charged when bound at the active site. Mechanistic interpretations from inhibitor binding are in line with single occupancy model for quinol oxidation and structural analysis supports the proposed proton transfer pathway. For functional insight into the enzyme mechanism, redox-sensitive protonation changes were studied by Fourier transform infrared spectroscopy. The protein purification procedure was optimized for less delipidation and the isolated enzyme was more active. Furthermore, two new phospholipids were identified in the X-ray structures, including a cardiolipin. Strikingly, conserved lipid binding cavities were observed in structural comparison with homologous enzymes. The functional role of tightly bound phospholipids will be discussed. Finally, the Qo site is a target for various compounds of agricultural and pharmaceutical importance. Importantly, the X-ray structures permit detailed analysis of the molecular reasons for acquired resistance to and treatment failure of Qo site inhibitors, such as atovaquone, that is used to treat malaria and pneumonia, as discussed herein.
Nitric oxide (NO) is a potent mediator with pleiotropic functions such as inhibition of platelet aggregation, smooth muscle relaxation and regulation of neuronal transmission. These effects are mostly mediated by intracellular NO-sensitive guanylyl cyclases (GCs) which convert GTP into the second messenger, cGMP. This messenger in turn activates multiple downstream effectors such as cGMP-dependent protein kinases, cGMP-regulated ion channels and cGMPdependent phosphodiesterases. Mammalian NO-sensitive GCs are obligate heterodimers of an α and β subunit each. Given that these enzymes play a key role in cGMP-mediated pathways, one may anticipate that mechanisms other than allosteric activation via NO may exist to regulate the production and turnover of cGMP. In this thesis, novel aspects of the regulation of the most abundantly expressed GC heterodimer α1β1 are presented.
A possible mechanism of regulation that was tested here, is tyrosine phosphorylation. Using anti-phosphotyrosine antibodies, the phosphorylation of the β1 subunit was detected after incubation of β1-overexpressing COS-1 cells with protein tyrosine phosphatase (PTP) inhibitors such as pervanadate and bpV(phen). β1 phosphorylation on tyrosines was also observed in PC-12 cells which endogenously express GC and in rat aorta after inhibition of PTPs. Furthermore, hydrogen peroxide was found to be a physiological stimulus for the induction of reversible β1 tyrosine phosphorylation in intact cells. Using phenylalanine mutants of different tyrosines, residue 192 (Y192) of β1 was identified as the major phosphorylation site. Consistent with this finding, sequence analyses showed that Y192 forms part of a motif that resembles a preferential target site for Src-like kinases. When tyrosine-phosphorylated, this motif exposes a typical SH2 docking site for members of the Src kinase family.
Experiments with inhibitors of Src kinases, PP1 and PP2, clearly showed that phosphorylation of Y192 is Src-dependent. Preincubation of β1-expressing cells with these inhibitors significantly reduced the level of phosphorylated β1 after bpV(phen) treatment. Furthermore, co-expression of β1 with Src led to a strong phosphorylation of this subunit. Co-precipitation experiments showed that Src interacts with GC. Interestingly, kinases of the Src family are recruited to β1 via the SH2 domain upon phosphorylation of Y192. Together, these results indicate that Src kinases phosphorylate tyrosine 192 thereby creating a docking site for their own SH2 domains. Kinase bound to GC may then catalyze phosphorylation of GC or other downstream effectors. Inhibition of PTPs altered GC activity in two ways: it increased both the basal activity and the YC-1- and BAY 41-2272-stimulated activity two-fold, and it reduced the sensitivity of the enzyme towards NO. The detailed mechanism of action is still unknown, but experiments using the mutant β1[Y192F] demonstrated that residue 192 is not responsible for these effects.
Another major focus of this thesis was the identification of novel GC binding proteins. Using the yeast two-hybrid approach, the carboxy-terminal portion of a protein named AGAP1 (amino acid (aa) 399-804) was found to interact with the catalytic domain of α1 (aa 466-690) and with the regulatory domain of β1 (aa 1-348). Human AGAP1 is a multidomain protein of 804 amino acids with a calculated molecular mass of 89,1 kDa comprising an Arf-GAP (GAP:GTPase activating protein), a putative GTPase domain, two Ankyrin repeats and a PHdomain. Co-precipitation experiments using lysates from mammalian cells overexpressing both binding partners confirmed the interaction of AGAP1 with the GC subunits. Immunofluorescence analyses demonstrated that AGAP1 co-localizes with GC in the cytoplasm of COS-1 cells.
In Northern blots, AGAP1 mRNA was detected in various human and murine tissues showing a comparable expression pattern described for the mRNA of α1 and β1. Using an AGAP1-specific antibody, endogenous protein was precipitated from lysates of HEK-293 cells derived from human embryonic kidney. The same antibody efficiently cross-reacted with the rat homologue (rAGAP1) and immunoprecipitated endogenous rAGAP1 from lysates of PC-12 cells, aorta and heart. The molecular mass of rAGAP1 is larger than that of the human protein, possibly due to an additional exon present in the rat genome. Like β1, AGAP1 is a substrate for tyrosine kinases. Phosphorylation of AGAP1 was detected after inhibition of PTPs or by coexpression of Src. Furthermore, the kinase inhibitor PP2 strongly impaired phosphorylation of AGAP1 after pervanadate treatment suggesting that tyrosine kinases of the Src family are involved. Measurements of cGMP production showed that AGAP1 has no influence on the activity of NO-sensitive GC. Interestingly, inhibition of PTPs potently increased the complex formation between AGAP1 and GC indicating that the interaction between these two proteins is modulated by reversible tyrosine phosphorylation. Whether this effect is due to the phosphorylation of AGAP1 or GC is still unknown. AGAP1 associates with endosomes and exposes Arf-GAP activity towards Arf1 and Arf5 which are involved in vesicular transport. Thus, one may hypothesize that binding of α1β1 to AGAP1 targets GC to distinct subcellular compartments in close proximity to cGMP-dependent effectors, thereby optimizing cGMP generation and fostering cGMP-driven actions.
Taken together, these results demonstrate that beside the modulation of GC by NO the enzyme is regulated by tyrosine phosphorylation and interaction with AGAP1.